Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024)

Zevra Therapeutics' (ZVRA) quarterly Finished Goods came in at $1.1 million in Q3 2024, down 45.35% on a QoQ basis from $2.1 million in Q2 2024.

Analysis

Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024) Analysis & Trends

Zevra Therapeutics (ZVRA) has 2 years of Finished Goods data on file, last reported at $1.1 million in Q3 2024.

Quarterly Finished Goods changed N/A year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.1 million (changed N/A YoY) and the FY2023 annual result came in at $5.0 million, changed N/A from the prior year.
Finished Goods declined to $1.1 million in Q3 2024, from $2.1 million in the prior quarter.
In the past five years, Finished Goods ranged from a high of $5.1 million in Q1 2024 to a low of $1.1 million in Q3 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Zevra Therapeutics	734.60 Mn	513.03 Mn	38.18 Mn

Historic Data

Download Data